Who won big at #AACR18? Merck surges on Keytruda/chemo combo while Bristol-Myers shares tumble on comparison
Merck and Bristol-Myers Squibb both came to AACR looking to score points in their long-running slugfest over the lung cancer market. Both had promising results …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
